PROTON PUMP INHIBITORS MARKET ANALYSIS

Proton Pump Inhibitors Market Size and Trends

Global proton pump inhibitors market is estimated to be valued at USD 3.81 Bn in 2024 and is expected to reach USD 5.50 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.

To learn more about this report, request sample copy

Proton pump inhibitors are widely used for treatment of acid reflux diseases, peptic ulcers and other gastric disorders.  Increasing geriatric population who are more prone to such diseases, increasing awareness about treatment options and growing healthcare expenditure in emerging nations can boost demand for proton pump inhibitors. However, availability of alternative therapies and patent expiration of major drugs can hamper the market growth. Strong pipeline of novel drug candidates and increasing focus on emerging markets by key market players can offer new opportunities in the near future.

Rising prevalence of gastrointestinal disorders

Rising prevalence of gastrointestinal disorders such as acid reflux, heartburn and ulcers can drive the market growth. In 2022, according to the global guidelines published by World Gastroenterology Organization, over 25% of the world's population suffer from gastrointestinal issues at some point of life and this boosts demand for proton pump inhibitors that offer heartburn relief. Proton pump inhibitors work by reducing the amount of acid produced in the stomach and provide symptomatic relief for acid-related disorders. Various factors such as changing dietary habits, increased stress levels, consumption of alcohol, tobacco use and lack of physical activity contributes to increase in gastrointestinal disorders. According to the data published by World Health Organization, developing economies like India and China that are shifting towards more sedentary lifestyles and urbanization witness rise in obesity, and this boosts cases of acid reflux disease. For instance, in August 2023, according to the article published by Jaypee Hospital, there has been increase in the incidence of gastrointestinal (GI) disorders, prompting significant health concerns. The functionality of the GI system, which encompasses digestion, absorption, and waste elimination, is crucial for overall health. The increase in GI issues is attributed to various factors such as dietary habits, lifestyle shifts, environmental factors, and genetic predispositions.

Launch of new products

Global proton pump inhibitors market is witnessing growth due to rising number of new product launches by major pharma companies. PPIs are commonly used to reduce excess stomach acid and provide relief from conditions like acid reflux, ulcers and gastroesophageal reflux disease (GERD). Many companies are focusing on developing advanced and more effective PPI formulations to expand their portfolios and market share. Some new products offer dual relief from acid reflux and heartburn symptoms with just one pill. These work faster and for longer duration as compared to existing drugs. Other new launches combine PPIs with other medicines to manage concurrent conditions like H. pylori infection, which causes ulcers. Some companies are also developing PPIs with improved tolerability and reduced interaction with other medications. For instance, in March 2021, Xiromed LLC, a generic division of Insud Pharmaceuticals, introduced Omeprazole Delayed-Release Capsules, 20mg, as a generic equivalent of Prilosec.